High Yield Adjuvant for Monoclonal Antibody Production
The GERBU Adjuvant MTM is developed specifically for monoclonal antibody production and offers a high yield of IgG and fused
Read moreThe GERBU Adjuvant MTM is developed specifically for monoclonal antibody production and offers a high yield of IgG and fused
Read moreInflaRx N.V., a biopharmaceutical company in the clinical stage of developing anti-inflammatory therapeutics that target the complement system, has announced
Read moreGERBU’s Ready-to-use Immunoadjuvants are Economical and Animal Friendly A GERBU Biotechnik .pdf Brochure The unique GERBU Adjuvant PluS, Adjuvant S,
Read moreThe European Commission has authorised Sanofi and Regeneron’s Dupixent® (dupilumab) as the first and only therapeutic therapy for eosinophilic esophagitis.
Read moreEvusheld, a long-acting antibody (LAAB) combination from AstraZeneca, has received emergency use authorisation (EUA) by the FDA in the United
Read moreNew Phase 3 Data has shown a positive correlation between the human monoclonal antibody ADUHELM™ treatment effect on biomarkers and
Read moreGenentech’s investigational antibody for the treatment of early-stage Alzheimer’s disease, Gantenerumab, has been granted Breakthrough Therapy Designation by the U.S.
Read moreTezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read moreMerck (NYSE: MRK), known as MSD outside the United States and Canada, announced on Saturday the first results from the
Read moreCalypso Biotech, a leading biotechnology company in the development of Interleukin-15 (IL-15) targeted therapies, announces today completion of the dosing
Read more